Latham & Watkins Represents MeiraGTx in US$100 Million Ordinary Shares Offering

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical‑stage genetic medicines company, priced an underwritten offering of 11,111,111 ordinary shares at an offering price of US$9 per share. Gross proceeds to MeiraGTx from the offering were approximately US$100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering were sold by MeiraGTx. The offering closed on April 17, 2026.

Latham & Watkins LLP represented MeiraGTx in the offering with a corporate team led by partners Keith Halverstam and Jennifer Yoon, with associate Emma Gilmore and assistance from Catherine Fraser. Advice was also provided on healthcare and FDA regulatory matters by partner Nathan Beaton, with associate Evan Miller; and on investment advisers regulatory matters by partner Jennifer Tian.